dsm-firmenich presentan los primeros resultados mundiales comparando su novedosa formulación de CBD CBtru® con Epidiolex.
Este ensayo clínico de fase I muestra que CBtru® ofrece una biodisponibilidad equivalente o mejor que el estándar de referencia actual, con menos variabilidad entre sujetos y menor dependencia de los alimentos. Este sólido avance en la formulación podría transformar la administración de medicamentos con CBD con opciones de dosificación más convenientes y una mejor experiencia para el paciente.
Ponente:
Esta sesión dura 20 minutos.
Explore what newly published CBtru® pharmacokinetic data means for solid oral drug development—and why clinical evidence underpins meaningful innovation.
Discover how pharmaceutical quality management is advancing through proactive strategies that reduce risk, improve visibility, and support compliance.
Discover how dsm-firmenich and Bayer reduced vitamin C’s carbon footprint by 49% through renewable energy, process innovation, and sustainable pharma collaboration.
Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.
Don’t just take our word for it. Discover how our solutions can support your product development journey.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.